Goldman Sachs’s Tvardi Therapeutics TVRD Stock Holding History

Goldman Sachs’s Portfolio TVRD Stock Details TVRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-1,250	Closed	-$616K	–	6711
2017 Q3	$616K	Buy	1,250 +653	+109%	+$327K	﹤0.01%	4954
2017 Q2	$331K	Buy	+597	New	+$379K	﹤0.01%	5425

Other funds holding TVRD

SPC

Slate Path Capital New York $7.22B AUM 110.75% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AFG

American Financial Group Cincinnati, Ohio $284M AUM 12.01% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

SAM

Silvercrest Asset Management New York $15.3B AUM 40.56% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

DWAM

Duncan Williams Asset Management Memphis, Tennessee $444M AUM 24.78% 1-Year Est. Return

Goldman Sachs's TVRD Position: Q2 2026 in Review

Goldman Sachs sold out of Tvardi Therapeutics (TVRD) in Q2 2026, closing a stake of 23,898 shares — an estimated $76K sold.

Goldman Sachs first reported a position in TVRD in Q1 2016 and held it in 37 quarters. The position peaked at $9.62M in Q1 2021. 58 funds tracked by Wall St. Rank hold TVRD as of Q2 2026.

Goldman Sachs reported no remaining Tvardi Therapeutics position as of Q2 2026 after selling out during the quarter.
Goldman Sachs sold 23,898 Tvardi Therapeutics shares in Q2 2026, an estimated $76K.
Goldman Sachs first reported a position in Tvardi Therapeutics in Q1 2016 and held it in 37 quarters.
Goldman Sachs's Tvardi Therapeutics position peaked at $9.62M in Q1 2021.
58 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.